4 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 4 Phase 1, 4 Phase 2, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 4 | Recruiting 3, Withdrawn 1 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Gastroesophageal Junction: new trials by email Literature Review of Gastroesophageal Junction trials Research Report on Gastroesophageal Junction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Denikitug, Nivolumab, Ramucirumab - HER2-negative, Gastroesophageal Junction | Phase 2 | Recruiting | Gilead Sciences | 120 | 2026-08-07 | 2026-09-21 |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. [18F]FAPI-74 PET/CT - Esophageal Cancer, Gastric Cancer (GC) | Phase 3 | Recruiting | SOFIE | 200 | 2025-11-14 | 2026-10-19 |
| Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma Neoadjuvant chemo-immunotherapy - Gastroesophageal Junction, Gastric / Gastroesophageal Junction Adenocarcinoma | Not applicable | Not yet recruiting | Tang-Du Hospital | 30 | 2025-08-01 | 2025-07-29 |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 160 | 2024-09-20 | 2026-10-07 |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) Ramucirumab, Paclitaxel, Sacituzumab Tirumotecan - Gastroesophageal Junction, Gastroesophageal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 210 | 2024-08-07 | 2026-09-03 |
| Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients Cabotamig (ARB202) - Gastrointestinal Cancer, Cholangiocarcinoma | Phase 1 | Completed | Arbele Pty Ltd | 33 | 2022-05-30 | 2026-03-19 |
| An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Relatlimab + Nivolumab, Nivolumab, Paclitaxel - Gastric Cancer, Cancer of the Stomach | Phase 2 | Withdrawn | Bristol-Myers Squibb | 2019-10-31 | 2020-05-19 | |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation - Urinary Bladder Cancer, Melanoma | Phase 1 | Active not recruiting | USWM CT, LLC | 71 | 2017-05-15 | 2026-06-04 |
Esophageal Neoplasms (4) · Stomach Neoplasms (4) · Adenocarcinoma Of Esophagus (2) · Parkinson Disease 4, Autosomal Dominant Lewy Body (2) · Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Liposarcoma, Myxoid (1) · Liver Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1)
Digestive System Diseases (6) · Digestive System Neoplasms (6) · Gastrointestinal Diseases (6) · Neoplasms (6) · Neoplasms by Site (6) · Gastrointestinal Neoplasms (5) · Esophageal Diseases (4) · Stomach Diseases (4) · Head and Neck Neoplasms (3) · Carcinoma (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1)
Paclitaxel (3) · Ramucirumab (3) · Nivolumab (2) · patritumab deruxtecan (2) · Capecitabine (1) · Fluorouracil (1) · Leucovorin (1) · Levoleucovorin (1) · Oxaliplatin (1) · Radiation (1) · pembrolizumab (1) · relatlimab (1)
Merck Sharp & Dohme LLC (2) · Arbele Pty Ltd (1) · Bristol-Myers Squibb (1) · Gilead Sciences (1) · SOFIE (1) · Tang-Du Hospital (1) · USWM CT, LLC (1)
United States (6) · Australia (3) · Brazil (3) · Chile (3) · France (3) · Germany (3) · Italy (3) · South Korea (3) · Canada (2) · China (2) · Norway (2) · Spain (2) · Switzerland (2) · Taiwan (2) · Argentina (1)
David Hong, MD (1) · Sherly Mosessian, Ph.D (1)
2023 (2), 2018 (1), 2025 (1)